All In Biotech

Drug Trial Radar · NCT00198445

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution, 0.1% vs. Placebo for Treatment of Ocular Inflammation Following Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Mar 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 527 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

527

Actual

Start

May 2003

Primary completion

Jan 2004

Study completion Jan 2004

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to investigate the efficacy of bromfenac sodium ophthalmic solution 0.09% for treatment of post-operative ocular inflammation in subjects who undergo cataract extraction and intraocular lens implantation. The secondary objective was to investigate the safety and tolerability of the same.

Conditions

  • Postoperative Complications
  • Cataract

Interventions

  • BromfenacDrug

    One drop in study eye every 12 hours for 14 days

  • PlaceboDrug

    One drop in study eye every 12 hours for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Inflammation ScoreTime frame: Visit 4 (Day 15)

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Harold A Helms, MD

    Birmingham, Alabama

  • Eye Care Arkansas, PA

    Little Rock, Arkansas

  • UCI, Department of Ophthalmology

    Irvine, California

  • Anesthetic Eye Care Institute

    Newport Beach, California

  • Richard A Lewis, MD

    Sacramento, California

  • Eye Care of San Diego

    San Diego, California

  • Santa Clara Valley Medical Center

    San Jose, California

  • E Randy Craven, MD

    Littleton, Colorado

  • The Eye Care Group

    New Haven, Connecticut

  • Cohen Laser Vision Center

    Boca Raton, Florida

  • Brandon Cataract Center & Eye Clinic

    Brandon, Florida

  • Marvin E Greenberg, MD, PA

    Tamarac, Florida

  • Jack Daubert, MD

    West Palm Beach, Florida

  • Advanced Eye Care, PC

    Fort Oglethorpe, Georgia

  • Saltzer Medical Group, PA

    Nampa, Idaho

  • Donald E Beahm, MD

    Great Bend, Kansas

  • Cincinnati Eye Institute NKY

    Edgewood, Kentucky

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Stevenson Medical Surgical Eye Center

    New Orleans, Louisiana

  • Cornea Consultants

    Boston, Massachusetts

  • Great Lakes Eye Care

    Saint Joseph, Michigan

  • Hunkeler Eye Institute

    Kansas City, Missouri

  • Arthur J Weinstein, MD

    Albuquerque, New Mexico

  • Ophthalmic Consultants of Long Island

    Rockville Centre, New York

  • Horizon Eye Care

    Charlotte, North Carolina

  • Dean A McGee Eye Institute

    Oklahoma City, Oklahoma

  • The Eye Institute

    Tulsa, Oklahoma

  • Casey Eye Institute

    Portland, Oregon

  • Eye Health Northwest

    Portland, Oregon

  • Scheie Eye Institute

    Philadelphia, Pennsylvania

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota

  • Middle Tennessee Eye Associates

    Cookeville, Tennessee

  • Texan Eye Care PA

    Austin, Texas

  • Ophthalmology Service, Brooke Army Medical Center

    Fort Sam Houston, Texas

  • Ophthalmology Visual Science

    Galveston, Texas

  • Houston Eye Associates

    Houston, Texas

  • David G Shulman, MD

    San Antonio, Texas

  • Central Texas Eye Center

    San Marcos, Texas

  • Virginia Eye Consultants

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.